Medartis
Medartis AG, headquartered in Switzerland (CH), is a leading player in the medical device industry, specialising in innovative solutions for the treatment of bone fractures and deformities. Founded in 1997, the company has established a strong presence in Europe, Asia, and the Americas, focusing on advanced surgical techniques and high-quality implants. Medartis is renowned for its unique product offerings, including the patented locking plate systems and comprehensive range of surgical instruments designed for orthopaedic and trauma surgery. These products are distinguished by their precision engineering and commitment to enhancing patient outcomes. With a solid market position, Medartis has achieved significant milestones, including numerous regulatory approvals and partnerships with healthcare professionals worldwide, solidifying its reputation as a trusted provider in the orthopaedic sector.
DitchCarbon Score
How does Medartis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medartis's score of 56 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medartis's reported carbon emissions
In 2023, Medartis AG reported total greenhouse gas emissions of approximately 6,857,000 kg CO2e, with significant contributions from Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions amounted to about 955,300 kg CO2e, while Scope 2 emissions were approximately 604,140 kg CO2e. The company also disclosed Scope 3 emissions, which included various categories such as business travel (570,600 kg CO2e) and purchased goods and services (2,498,000 kg CO2e). Medartis has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 65% by 2033, using 2023 as the base year. Additionally, the company plans to ensure that 67% of its suppliers, based on emissions from purchased goods and services, will have science-based targets by 2029. For Scope 3 emissions, Medartis targets a reduction of 61.1% per million CHF value added by 2033, focusing on categories such as capital goods, upstream transportation, and waste generated in operations. These commitments align with industry standards and reflect Medartis's dedication to addressing climate change and reducing its carbon footprint in the healthcare equipment and supplies sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 795,000 | 000,000 | 000,000 |
| Scope 2 | 831,000 | 000,000 | 000,000 |
| Scope 3 | 689,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medartis is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
